Affimed (AFMD) Scheduled to Post Earnings on Thursday

Affimed (NASDAQ:AFMD - Get Free Report) is scheduled to release its earnings data before the market opens on Thursday, November 14th. Analysts expect Affimed to post earnings of ($1.14) per share for the quarter. Persons that are interested in participating in the company's earnings conference call can do so using this link.

Affimed (NASDAQ:AFMD - Get Free Report) last issued its quarterly earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.09). Affimed had a negative return on equity of 155.30% and a negative net margin of 2,922.74%. The business had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.67 million. On average, analysts expect Affimed to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Affimed Price Performance

AFMD traded up $0.26 during trading on Thursday, reaching $3.83. 230,034 shares of the company's stock were exchanged, compared to its average volume of 271,480. The company's fifty day simple moving average is $3.53 and its 200-day simple moving average is $4.58. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.71 and a current ratio of 2.71. Affimed has a 1 year low of $2.92 and a 1 year high of $8.95.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on AFMD shares. HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Affimed in a research report on Friday, September 6th. Cantor Fitzgerald reissued an "overweight" rating on shares of Affimed in a report on Monday, September 9th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $20.00.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.